aluates Reports

$ 0.0

Automative

Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Research Report 2025

Published Date: April 2025

Report Code: QYRE-Auto-38Q13270

Global Chronic Graft versus host Disease cGVHD Treatment Market Research Report 2023

BUY CHAPTERS

Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Research Report 2025

Code: QYRE-Auto-38Q13270

Report

April 2025

Pages:77

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Merck KGaA

Sanofi SA

Novartis

Bristol–Myers Squibb

Pfizer Inc

Roche Holding AG

Johnson & Johnson

Eli Lilly and Company

Abbott Laboratories

Takeda Pharmaceutical Company

Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size

The global market for Chronic Graft-versus-host Disease (cGVHD) Treatment was valued at US$ 1666 million in the year 2024 and is projected to reach a revised size of US$ 2889 million by 2031, growing at a CAGR of 8.3% during the forecast period.

Chronic Graft-versus-host Disease (cGVHD) Treatment Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Graft-versus-host Disease (cGVHD) Treatment.

The Chronic Graft-versus-host Disease (cGVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Graft-versus-host Disease (cGVHD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Graft-versus-host Disease (cGVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chronic Graft-versus-host Disease (cGVHD) Treatment Market Report

Report Metric	Details
Report Name	Chronic Graft-versus-host Disease (cGVHD) Treatment Market
Accounted market size in year	US$ 1666 million
Forecasted market size in 2031	US$ 2889 million
CAGR	8.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Corticosteroids mTOR Inhibitors Tyrosine Kinase Inhibitors Monoclonal Antibodies Others
Segment by Application	Hospitals Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, Takeda Pharmaceutical Company
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Chronic Graft-versus-host Disease (cGVHD) Treatment Market growing?

Ans: The Chronic Graft-versus-host Disease (cGVHD) Treatment Market witnessing a CAGR of 8.3% during the forecast period 2025-2031.

What is the Chronic Graft-versus-host Disease (cGVHD) Treatment Market size in 2031?

Ans: The Chronic Graft-versus-host Disease (cGVHD) Treatment Market size in 2031 will be US$ 2889 million.

Who are the main players in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market report?

Ans: The main players in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market are Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, Takeda Pharmaceutical Company

What are the Application segmentation covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market report?

Ans: The Applications covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market report are Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market report?

Ans: The Types covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment Market report are Corticosteroids, mTOR Inhibitors, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others

Recommended Reports

Chronic Disease Therapies

Cell & Gene Therapy

Hematological Oncology

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Corticosteroids

1.2.3 mTOR Inhibitors

1.2.4 Tyrosine Kinase Inhibitors

1.2.5 Monoclonal Antibodies

1.2.6 Others

1.3 Market by Application

1.3.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Perspective (2020-2031)

2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Growth Trends by Region

2.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Region (2020-2025)

2.2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031)

2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Dynamics

2.3.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends

2.3.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers

2.3.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges

2.3.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue

3.1.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue (2020-2025)

3.1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue

3.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio

3.4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024

3.5 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment Head office and Area Served

3.6 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application

3.7 Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Type

4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Type (2020-2025)

4.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031)

5 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Application

5.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic Market Size by Application (2020-2025)

5.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)

6.2 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)

6.4 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)

7.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)

7.4 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)

8.2 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)

9.2 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)

9.4 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (2020-2031)

10.2 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Merck KGaA

11.1.1 Merck KGaA Company Details

11.1.2 Merck KGaA Business Overview

11.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.1.4 Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.1.5 Merck KGaA Recent Development

11.2 Sanofi SA

11.2.1 Sanofi SA Company Details

11.2.2 Sanofi SA Business Overview

11.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.2.4 Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.2.5 Sanofi SA Recent Development

11.3 Novartis AG

11.3.1 Novartis AG Company Details

11.3.2 Novartis AG Business Overview

11.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.3.4 Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.3.5 Novartis AG Recent Development

11.4 Bristol Myers Squibb

11.4.1 Bristol Myers Squibb Company Details

11.4.2 Bristol Myers Squibb Business Overview

11.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.4.4 Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.4.5 Bristol Myers Squibb Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.5.4 Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Roche Holding AG

11.6.1 Roche Holding AG Company Details

11.6.2 Roche Holding AG Business Overview

11.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.6.4 Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.6.5 Roche Holding AG Recent Development

11.7 Johnson & Johnson

11.7.1 Johnson & Johnson Company Details

11.7.2 Johnson & Johnson Business Overview

11.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.7.4 Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.7.5 Johnson & Johnson Recent Development

11.8 Eli Lilly and Company

11.8.1 Eli Lilly and Company Company Details

11.8.2 Eli Lilly and Company Business Overview

11.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.8.4 Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.8.5 Eli Lilly and Company Recent Development

11.9 Abbott Laboratories

11.9.1 Abbott Laboratories Company Details

11.9.2 Abbott Laboratories Business Overview

11.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.9.4 Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.9.5 Abbott Laboratories Recent Development

11.10 Takeda Pharmaceutical Company

11.10.1 Takeda Pharmaceutical Company Company Details

11.10.2 Takeda Pharmaceutical Company Business Overview

11.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction

11.10.4 Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

11.10.5 Takeda Pharmaceutical Company Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Merck KGaA

Sanofi SA

Novartis

Bristol–Myers Squibb

Pfizer Inc

Roche Holding AG

Johnson & Johnson

Eli Lilly and Company

Abbott Laboratories

Takeda Pharmaceutical Company

List of Tables

Table 1. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Corticosteroids

Table 3. Key Players of mTOR Inhibitors

Table 4. Key Players of Tyrosine Kinase Inhibitors

Table 5. Key Players of Monoclonal Antibodies

Table 6. Key Players of Others

Table 7. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2025)

Table 11. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2026-2031)

Table 13. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Trends

Table 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers

Table 15. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges

Table 16. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints

Table 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players (2020-2025)

Table 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)

Table 20. Ranking of Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Headquarters and Area Served

Table 23. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Product and Application

Table 24. Global Key Players of Chronic Graft-versus-host Disease (cGVHD) Treatment, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2020-2025)

Table 28. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Type (2026-2031)

Table 30. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2020-2025)

Table 32. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Application (2026-2031)

Table 34. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 49. Merck KGaA Company Details

Table 50. Merck KGaA Business Overview

Table 51. Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 52. Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 53. Merck KGaA Recent Development

Table 54. Sanofi SA Company Details

Table 55. Sanofi SA Business Overview

Table 56. Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 57. Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 58. Sanofi SA Recent Development

Table 59. Novartis AG Company Details

Table 60. Novartis AG Business Overview

Table 61. Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 62. Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 63. Novartis AG Recent Development

Table 64. Bristol Myers Squibb Company Details

Table 65. Bristol Myers Squibb Business Overview

Table 66. Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 67. Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 68. Bristol Myers Squibb Recent Development

Table 69. Pfizer Company Details

Table 70. Pfizer Business Overview

Table 71. Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 72. Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 73. Pfizer Recent Development

Table 74. Roche Holding AG Company Details

Table 75. Roche Holding AG Business Overview

Table 76. Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 77. Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 78. Roche Holding AG Recent Development

Table 79. Johnson & Johnson Company Details

Table 80. Johnson & Johnson Business Overview

Table 81. Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 82. Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 83. Johnson & Johnson Recent Development

Table 84. Eli Lilly and Company Company Details

Table 85. Eli Lilly and Company Business Overview

Table 86. Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 87. Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 88. Eli Lilly and Company Recent Development

Table 89. Abbott Laboratories Company Details

Table 90. Abbott Laboratories Business Overview

Table 91. Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 92. Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 93. Abbott Laboratories Recent Development

Table 94. Takeda Pharmaceutical Company Company Details

Table 95. Takeda Pharmaceutical Company Business Overview

Table 96. Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Product

Table 97. Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025) & (US$ Million)

Table 98. Takeda Pharmaceutical Company Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

Table 102. Authors List of This Report

List of Figures

Figure 1. Chronic Graft-versus-host Disease (cGVHD) Treatment Picture

Figure 2. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Type: 2024 VS 2031

Figure 4. Corticosteroids Features

Figure 5. mTOR Inhibitors Features

Figure 6. Tyrosine Kinase Inhibitors Features

Figure 7. Monoclonal Antibodies Features

Figure 8. Others Features

Figure 9. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Application: 2024 VS 2031

Figure 11. Hospitals Pharmacies Case Studies

Figure 12. Retail Pharmacies Case Studies

Figure 13. Online Pharmacies Case Studies

Figure 14. Chronic Graft-versus-host Disease (cGVHD) Treatment Report Years Considered

Figure 15. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region: 2024 VS 2031

Figure 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Players in 2024

Figure 19. Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2024

Figure 21. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)

Figure 23. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)

Figure 27. Germany Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Region (2020-2031)

Figure 35. China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)

Figure 43. Mexico Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Country (2020-2031)

Figure 47. Turkey Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Merck KGaA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 51. Sanofi SA Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 52. Novartis AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 53. Bristol Myers Squibb Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 54. Pfizer Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 55. Roche Holding AG Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 56. Johnson & Johnson Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 57. Eli Lilly and Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 58. Abbott Laboratories Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 59. Takeda Pharmaceutical Company Revenue Growth Rate in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cell Therapy Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oncolytic Virus Drug Treatment Market Research Report 2025

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global CGT Drugs Market Research Report 2025

Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Still s Disease Treatment Market Research Report 2025

Chronic Metabolic Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drug Delivery Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Scar Removal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Critical Care Therapeutics Market Research Report 2025

Global Treatment Planning Software Market Research Report 2025

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gynecological Cancers Drug Market Research Report 2025

Global Pediatric Oncology Treatment Market Research Report 2025

Ophthalmology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Dengue Fever Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rheumatology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19Z7671

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10V14317

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10O5919

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4I19963

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions